Side-by-side comparison
Amgen vs Bristol-Myers Squibb
As of Sep 25, 2026, P/E is 25.8x for Amgen vs 13.8x for Bristol-Myers Squibb; P/S is 5.9x for Amgen vs 2.6x for Bristol-Myers Squibb; revenue growth is 9.1% for Amgen vs 3.1% for Bristol-Myers Squibb; net margin is 23.0% for Amgen vs 18.9% for Bristol-Myers Squibb.
Key metrics
| Metric | AMGN | BMY |
|---|---|---|
| Price | $414.61 | $62.86 |
| Market cap | $224.15B | $128.41B |
| P/E | 25.8x (#2) | 13.8x (#1) |
| P/S | 5.9x (#2) | 2.6x (#1) |
| Revenue growth | 9.1% (#1) | 3.1% (#2) |
| Operating margin | 30.0% (#1) | — |
| Net margin | 23.0% (#1) | 18.9% (#2) |
| Debt / equity | 4.44 (#2) | 1.89 (#1) |
| 1-year return | +51.9% (#1) | +42.5% (#2) |
| Research score | 67/100 (#2) | 71/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General